CHRS - Coherus BioSciences - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CHRS is currently covered by 11 analysts with an average price target of $10.88. This is a potential upside of $9.64 (777.42%) from yesterday's end of day stock price of $1.24.

Coherus BioSciences's activity chart (see below) currently has 72 price targets and 82 ratings on display. The stock rating distribution of CHRS is 18.18% HOLD and 81.82% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 6.73% with an average time for these price targets to be met of 75.23 days.

Highest price target for CHRS is $14, Lowest price target is $1.5, average price target is $10.88.

Most recent stock forecast was given by ASHWANI VERMA from UBS on 16-Aug-2024. First documented stock forecast 27-Jul-2016.

Currently out of the existing stock ratings of CHRS, 6 are a HOLD (18.18%), 27 are a BUY (81.82%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

1.5

$0.11 (7.91%)

7

21 days ago

0/3 (0%)

$0.24 (19.05%)

Buy

12

$10.61 (763.31%)

12

1 months 1 days ago

0/16 (0%)

$10.68 (809.09%)

Buy

7

$5.61 (403.60%)

7

3 months 24 days ago

0/5 (0%)

$4.91 (234.93%)

Hold

22

9 months 29 days ago

3/8 (37.5%)

$7.72 (54.06%)

181

Buy

20

9 months 30 days ago

0/3 (0%)

$14.89 (291.39%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CHRS (Coherus BioSciences) average time for price targets to be met?

On average it took 75.23 days on average for the stock forecasts to be realized with a an average price target met ratio 6.73

Which analyst has the current highest performing score on CHRS (Coherus BioSciences) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on CHRS (Coherus BioSciences)?

Jason Mccarthy works at MAXIM GROUP and has 7 price targets and 4 ratings on CHRS

Which analyst is the currently most bullish on CHRS (Coherus BioSciences)?

Michael Ulz with highest potential upside - $28.61

Which analyst is the currently most reserved on CHRS (Coherus BioSciences)?

Jason Mccarthy with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?